Honda Motor Company Ltd. Common Stock vs Organon & Co. Common Stock — how do they compare? Honda Motor Company Ltd. Common Stock trades at $33.67 (market cap $43.08B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Honda Motor Company Ltd. Common Stock is far larger — about 11.9× Organon & Co. Common Stock's market cap, and Honda Motor Company Ltd. Common Stock pays the higher dividend (4%). Which is the better fit depends on your goals — on Pluang, investors hold Honda Motor Company Ltd. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| HMC | OGN | |
|---|---|---|
Market Cap | $43.08B | $3.62B |
Volume | 823,318 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $33.45 | $13.81 |
52-Week Low | $23.49 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $40.26B | $11.04B |
Dividend Yield | 4% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Honda Motor Co. (HMC) trades at $33.33, up 2.05% with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with revenue growth to $22.5T in 2026 but negative net income margins, while valuation metrics appear attractive with P/S of 0.32 and EV/EBITDA of 4.92. Recent news highlights strategic investments in hybrid technology and cost-cutting initiatives.
HMC presents a value opportunity with reasonable valuations and positive earnings surprises, though profitability challenges and competitive pressures create headwinds. Analyst consensus leans moderate buy with institutional interest, but investors should weigh cost reduction progress against margin pressures in the evolving auto industry.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Honda Motor manufactures automobiles, motorcycles, power products, and related financial services. Its brands serve consumer and commercial transportation markets globally.
Read more on HMC →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →